Esperion Therapeutics (ESPR) announced Monday morning that the FDA has confirmed that the company's LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
from RTT - Before the Bell http://ift.tt/2mPCAh6
via IFTTT
No comments:
Post a Comment